Episode 85: Every angle on Biogen's shocking Alzheimer's news
What exactly is Biogen doing? When is a press release worth $12 billion? And what should patients make of whiplashing news? We're devoting this entire episode to Biogen's stunning announcement that aducanumab, its once-discarded treatment for Alzheimer's disease, is getting a second life.
24 Oct 2019
Episode 22: Biotech's battle for talent, Sanofi's second act, and climbing Mt. Everest
What juicy perks do biotech startups offer to lure increasingly hard-to-find talent? How does Sanofi plan to make up for lost time in the lucrative field of oncology? And veteran biotech journalist Luke Timmerman talks about what it's like to climb Mt. Everest.
2 Aug 2018
Episode #8 - Megamergers, migraines, and biotech's Four Horsemen
What's a good use of $64 billion? Is Big Biotech boring now? And what's the best way to sell hair restoration products to men?
26 Apr 2018
Episode 92: The decade in breakthroughs, the year in bad CEOs, and the viruses that cure disease
Which drug defined the decade? Who's the worst CEO in biopharma? And how does gene therapy actually work?
19 Dec 2019
Most Popular Podcasts
Episode 66: The future of cancer treatment, blockbusters interrupted, & an infamous biotech party
Who won ASCO? Is pharma sandbagging its blockbusters? And what do gladiators have to do with biotech?
6 Jun 2019
Episode #7 - Coke and Pepsi of lung cancer, a debatable drug price, and a cure for capitalism
Is Bristol-Myers Squibb into self-sabotage? Is Congress coming for Gut Guy? And why does Goldman Sachs love money so much?
19 Apr 2018
Episode 24: A lesson in startup jargon, pharma's bare Alzheimer's cupboard, and the cost of CAR-T
How much is a shot at curing cancer worth? Where are all the drugs for late-stage Alzheimer's disease? And what on Earth is an "oversubscribed Series A round"?
16 Aug 2018
Episode 53: How startups stop, the new FDA boss, and Theranos on the big screen
Who deserves credit for a new gene therapy? How do you push stop on a startup? And what does MC Hammer have to do with Theranos?
14 Mar 2019
Episode 21 - A debatable Alzheimer's breakthrough, Gilead's golden age, and "robust" data
What qualifies as "robust" when it comes to data? Is digital health a bubble? And can Gilead Sciences survive without men named John?
26 Jul 2018
Episode 86: Drugs that don't work, wearables in the desert, & excess 'innovation'
When should a drug be pulled from shelves? How do you pronounce "HLTH?" And how does Ann Coulter decide what to tweet?
31 Oct 2019
Episode 90: Biogen's big reveal, hot takes on Alzheimer's, & the science of one-eyed sheep
How do you know if a "positive" study is positive? And how did one-eyed sheep lead to a drug for certain cancers?
5 Dec 2019
Episode 42: Parsing Bristol-Myers-Celgene, grousing about JPM, and how to not be boring
Are megamergers bad for business? Is it time for biotech's biggest gathering to find a new home? And can a "need" be anything but "unmet"?
3 Jan 2019
Episode 43: A people's history of J.P. Morgan
Do drug developers tip well? Is biotech safe for 6-year-olds? And what's a Cable Car Cosmo?
10 Jan 2019
Episode 17: A friendly FDA, biosimilar awkwardness and how to sell drugs in China
How did the FDA become so friendly to the drug industry? The thorny issue of using 23andMe to unite families separated at the border, and Rebecca explains how drugs are priced in China.
28 Jun 2018
Episode #6 - Biotech buyouts, CEO breakups, and The Rock does CRISPR
Why are biotech investors suddenly so exuberant? What does it mean when a CEO scrubs his LinkedIn profile? And can CRISPR turn your dog into a winged hellhound bent on destroying Chicago?
12 Apr 2018
Episode 69: The future of AbbVieGan, the dogma of amyloid, & some questionable biotech marketing
Can Botox make Big Pharma attractive? What qualifies as a "cabal"? And will the CRISPR patent fight outlive us all?
27 Jun 2019
Episode 57: Trump’s drug pricing foot soldier, Gilead’s uncertain future, & transpacific angst
How do you sell lefty ideas to righty politicians? What’s going on at Gilead Sciences? And why are biotech investors freaking out?
11 Apr 2019
Episode 87: Derek Lowe on China's new Alzheimer's drug, blockbuster fish oil, & STAT's birthday
Why hope for China's new Alzheimer's drug turned into skepticism ? Is three a crowd in CAR-T? And what's a Bionomy?
7 Nov 2019
Episode 47: A bad day for bold biotech, campaign 2020, and where do drugs come from?
Are we underestimating biology? Will Hot 97 decide the presidency? And who owns the scientific means of production?
7 Feb 2019
Episode 19: Trump's telephonic prowess, Biogen's mysterious future, & the rise of 'hypelines'
Can phone calls bring down drug prices? Do mom-and-pop investors have a prayer against hedge funds? And how do you know whether an Alzheimer's drug actually works?
12 Jul 2018